Uncover key drivers, emerging technologies, and competitive movements shaping the gastrointestinal stromal tumor market from 2026–2035 with trusted insights from The Business Research Company
How much is the Gastrointestinal Stromal Tumor Market valued at in 2026, and what valuation is forecast for 2030?
The gastrointestinal stromal tumor market size has recently shown strong expansion. It is anticipated to increase from $1.36 billion in 2025 to $1.46 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. During the past period, this growth was primarily due to the approval of imatinib therapy, advancements in tumor classification, the expansion of oncology care centers, a rise in awareness regarding rare gi tumors, and the availability of surgical interventions.
The market size for gastrointestinal stromal tumors is expected to experience substantial growth in the upcoming years. It is projected to expand to $1.98 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This anticipated growth can be attributed to the development of advanced targeted therapies, an increase in precision diagnostics, a rise in clinical trials, the expansion of personalized cancer treatment options, and improved survival outcomes for patients. Throughout the forecast period, significant trends include the increasing use of targeted tyrosine kinase inhibitors, a greater focus on molecular tumor profiling, the widespread adoption of precision oncology approaches, an increase in combined surgical and drug therapies, and enhanced long-term disease management.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp
What Drivers Are Influencing The Growth Of The Gastrointestinal Stromal Tumor Market?
The increasing occurrence of stomach cancer is projected to stimulate the expansion of the gastrointestinal stromal tumor market in the future. This condition, stomach cancer, involves the uncontrolled proliferation of cancerous cells within the stomach’s inner lining. Although gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are recognized as separate entities from stomach cancer. It has been noted that patients with GISTs face an increased risk of developing other cancers, including small bowel adenocarcinoma, particularly when two distinct tumors collide and merge into one. As an illustration, the American Cancer Society, a professional organization based in the US, reported in January 2024 that approximately 26,890 fresh diagnoses of stomach cancer and 10,880 fatalities are projected in the U.S. for 2024, representing 1.5% of all new cancer diagnoses. Consequently, the rising prevalence of stomach cancer is fueling the expansion of the gastrointestinal stromal tumor market.
What Segments Are Included Within The Gastrointestinal Stromal Tumor Market?
The gastrointestinal stromal tumor market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users
Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies
Which Trends Are Expected To Influence The Gastrointestinal Stromal Tumor Market In The Upcoming Years?
Major companies operating within the gastrointestinal stromal tumor market are actively developing novel drugs, such as signal transduction and targeted therapy, with the aim of enhancing treatment effectiveness, overcoming resistance to current therapies, and addressing unmet clinical requirements. Signal transduction and targeted therapy are approaches designed to inhibit or alter specific cellular signaling pathways crucial for tumor growth and survival. For example, in November 2025, Ascentage Pharma Group International Inc., a commercial-stage biopharmaceutical firm based in China, revealed the publication of Phase Ib clinical data for olverembatinib (HQP1351) in Signal Transduction and Targeted Therapy. This report highlighted promising efficacy and safety results in SDH-deficient gastrointestinal stromal tumors (GIST) and identified a novel antitumor mechanism involving lipid metabolism modulation.
Who Are The Major Companies Operating In The Gastrointestinal Stromal Tumor Market?
Major companies operating in the gastrointestinal stromal tumor market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Gastrointestinal Stromal Tumor Market?
North America was the largest region in the gastrointestinal stromal tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Gastrointestinal Stromal Tumor Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp
Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2026, By The Business Research Company
Gastrointestinal Endoscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report
Gastric Cancer Diagnostic Procedure Market Report 2026
Germ Cell Tumor Market Report 2026
https://www.thebusinessresearchcompany.com/report/germ-cell-tumor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model